File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Estrogen receptor subtypes in ovarian cancer: A clinical correlation

TitleEstrogen receptor subtypes in ovarian cancer: A clinical correlation
Authors
Issue Date2008
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.greenjournal.org
Citation
Obstetrics And Gynecology, 2008, v. 111 n. 1, p. 144-151 How to Cite?
AbstractOBJECTIVE: To study the distribution of estrogen receptor (ER) subtypes in ovarian tumors and to correlate the levels of expression with clinical factors. METHODS: Estrogen receptor-α (ERα) and β-mRNA expressions in 58 normal, 25 borderline, and 161 malignant ovarian tissue samples were determined by quantitative real-time polymerase chain reaction. The expression levels were correlated with clinical data, including the histologic subtypes, the stage of the disease, and the disease-free and overall survival, with a median follow-up of 80 months. RESULTS: Estrogen receptor-β (ERβ) expression, but not ERα, was significantly higher in normal tissues compared with malignant tissues (P<.001). Estrogen receptor-β expression was also significantly higher in stage I disease compared with stage II-IV disease (P<.001). A higher ERβ expression was found to be significantly associated with a longer disease-free survival (P=.007) as well as overall survival (P=.011). Estrogen receptor-β expression remained a significant predictor for disease-free survival and overall survival in multivariable analysis that took into account other factors that were shown to be associated with survival in univariate analyses, including stage of disease, type of tumor (borderline or malignant), and optimal debulking. CONCLUSION: Loss of ERβ expression in ovarian tumors may be a feature of malignant transformation. Determining ER subtypes expression may improve response to hormonal therapy by tailoring the use of selective estrogen receptor modulators with different ER affinity in selected women. As a prognostic indicator, ERβ levels may be useful in deciding the need for and choice of adjuvant treatment in women with early ovarian cancers. © 2008 The American College of Obstetricians and Gynecologists.
Persistent Identifierhttp://hdl.handle.net/10722/87026
ISSN
2015 Impact Factor: 5.656
2015 SCImago Journal Rankings: 2.899
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, KKLen_HK
dc.contributor.authorWei, Nen_HK
dc.contributor.authorLiu, SSen_HK
dc.contributor.authorXiaoYun, Len_HK
dc.contributor.authorCheung, ANen_HK
dc.contributor.authorNgan, HYSen_HK
dc.date.accessioned2010-09-06T09:24:21Z-
dc.date.available2010-09-06T09:24:21Z-
dc.date.issued2008en_HK
dc.identifier.citationObstetrics And Gynecology, 2008, v. 111 n. 1, p. 144-151en_HK
dc.identifier.issn0029-7844en_HK
dc.identifier.urihttp://hdl.handle.net/10722/87026-
dc.description.abstractOBJECTIVE: To study the distribution of estrogen receptor (ER) subtypes in ovarian tumors and to correlate the levels of expression with clinical factors. METHODS: Estrogen receptor-α (ERα) and β-mRNA expressions in 58 normal, 25 borderline, and 161 malignant ovarian tissue samples were determined by quantitative real-time polymerase chain reaction. The expression levels were correlated with clinical data, including the histologic subtypes, the stage of the disease, and the disease-free and overall survival, with a median follow-up of 80 months. RESULTS: Estrogen receptor-β (ERβ) expression, but not ERα, was significantly higher in normal tissues compared with malignant tissues (P<.001). Estrogen receptor-β expression was also significantly higher in stage I disease compared with stage II-IV disease (P<.001). A higher ERβ expression was found to be significantly associated with a longer disease-free survival (P=.007) as well as overall survival (P=.011). Estrogen receptor-β expression remained a significant predictor for disease-free survival and overall survival in multivariable analysis that took into account other factors that were shown to be associated with survival in univariate analyses, including stage of disease, type of tumor (borderline or malignant), and optimal debulking. CONCLUSION: Loss of ERβ expression in ovarian tumors may be a feature of malignant transformation. Determining ER subtypes expression may improve response to hormonal therapy by tailoring the use of selective estrogen receptor modulators with different ER affinity in selected women. As a prognostic indicator, ERβ levels may be useful in deciding the need for and choice of adjuvant treatment in women with early ovarian cancers. © 2008 The American College of Obstetricians and Gynecologists.en_HK
dc.languageengen_HK
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.greenjournal.orgen_HK
dc.relation.ispartofObstetrics and Gynecologyen_HK
dc.rightsObstetrics and Gynecology. Copyright © Lippincott Williams & Wilkins.en_HK
dc.subject.meshAdenocarcinoma - metabolism - pathologyen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshCase-Control Studiesen_HK
dc.subject.meshCohort Studiesen_HK
dc.subject.meshEstrogen Receptor alpha - genetics - metabolismen_HK
dc.subject.meshEstrogen Receptor beta - genetics - metabolismen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGene Expression Profilingen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshNeoplasm Stagingen_HK
dc.subject.meshOvarian Neoplasms - metabolism - pathologyen_HK
dc.subject.meshOvary - pathologyen_HK
dc.subject.meshPilot Projectsen_HK
dc.subject.meshRNA, Messenger - metabolismen_HK
dc.subject.meshSurvival Analysisen_HK
dc.titleEstrogen receptor subtypes in ovarian cancer: A clinical correlationen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0029-7844&volume=111&spage=144&epage=151&date=2008&atitle=Estrogen+receptor+subtypes+in+ovarian+cancer:+a+clinical+correlationen_HK
dc.identifier.emailChan, KKL:kklchan@hkucc.hku.hken_HK
dc.identifier.emailLiu, SS:stephasl@hku.hken_HK
dc.identifier.emailCheung, AN:anycheun@hkucc.hku.hken_HK
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_HK
dc.identifier.authorityChan, KKL=rp00499en_HK
dc.identifier.authorityLiu, SS=rp00372en_HK
dc.identifier.authorityCheung, AN=rp00542en_HK
dc.identifier.authorityNgan, HYS=rp00346en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1097/01.AOG.0000296715.07705.e9en_HK
dc.identifier.pmid18165403-
dc.identifier.scopuseid_2-s2.0-37549048164en_HK
dc.identifier.hkuros141177en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-37549048164&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume111en_HK
dc.identifier.issue1en_HK
dc.identifier.spage144en_HK
dc.identifier.epage151en_HK
dc.identifier.eissn1873-233X-
dc.identifier.isiWOS:000252199900019-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridChan, KKL=8655666700en_HK
dc.identifier.scopusauthoridWei, N=23101332300en_HK
dc.identifier.scopusauthoridLiu, SS=37102450400en_HK
dc.identifier.scopusauthoridXiaoYun, L=54886720400en_HK
dc.identifier.scopusauthoridCheung, AN=54927484100en_HK
dc.identifier.scopusauthoridNgan, HYS=34571944100en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats